ClinicalTrials.gg
RecruitingNCT06655883Updated Sep 21, 2026

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

A Phase 3 interventional study of Suvorexant and Placebo in Insomnia, sponsored by Merck Sharp & Dohme LLC. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders — 5 open to participants now, 5 under way, 1 of them phase 3. suvorexant · Sleep Initiation and Maintenance Disorders.

Planned enrollment
5th of 38
300 · median 44
Started
2025
with 2 others
Phase 3
5 of 38
1 open now
Registered
34th of 38
by date
Lead sponsor
11 of 38
Merck Sharp & Dohme LLC

Among the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 3, and was the 34th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

5 of the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About suvorexant

suvorexant: first FDA approval 2014 (BELSOMRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a primary diagnosis of OUD according to Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (), and confirmed through the Mini International Neuropsychiatric Interview (MINI).
  • Is on a verified, stable dose of medications for opioid use disorder (MOUD) treatment.
  • Meets DSM-5 criteria for the diagnosis of Insomnia Disorder
  • Has a regular bedtime between 8 PM (20:00) and 1 AM (01:00) and is willing to maintain it for the duration of the study.
  • Has not used opioids for a period of at least 4 weeks before entering the study.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has current uncontrolled major co-morbid psychiatric illness including major depressive disorder, bipolar disorder, schizophrenia, or any psychiatric condition with psychotic features.
  • Has current diagnosis or history within 5 years of any of the following: narcolepsy, sleep paralysis, severe periodic limb movement disorder, restless leg syndrome, cataplexy, circadian rhythm sleep disorder, parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, rapid eye movement (REM) behavior disorder, significant degree of sleep-related breathing disorder, excessive daytime sleepiness (EDS), or primary hypersomnia.
  • Is at imminent risk of self-harm.
  • Has a known history of stroke that may confound the diagnosis of insomnia.
  • Has a movement disorder such as akinesia.
  • Has a history of hepatitis or live disease.
  • Has habitual use of central nervous system (CNS)-depressants or stimulants that may be responsible for the participant's disturbed sleep.
  • Has a history of , ≤3 years prior to start of study, with the exception of nonmelanoma skin cancer, prostate cancer or localized carcinoma in situ of the cervix.
  • Has a history of to more than 3 chemical classes of drugs, including prescription and over-the-counter medications.
  • Has donated blood products or had phlebotomy within 8 weeks prior to start of study.
  • Has a history of transmeridian travel within 2 weeks prior to start of study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Suvorexant

    Participants receive 10 mg of suvorexant for the first three nights, increased to 20 mg of suvorexant nightly thereafter at the investigator's discretion, for up to approximately 8 weeks.

    Drug: Suvorexant

  • Placebo comparator
    Placebo

    Participants receive suvorexant-matching placebo for up to approximately 8 weeks.

    Drug: Placebo

Interventions

  • Oral Tablet

    Also known as: MK-4305

  • DrugPlacebo

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total Sleep Time at Week 8

    Total sleep time will be measured in a sleep laboratory by polysomnography at the participant's habitual bedtime. Change from baseline in total sleep time at Week 8 will be reported.

    Time frame: Baseline and Week 8

  2. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 10 weeks

  3. Number of Participants Who Experience One or More Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that at any dose results in death, is life threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is another important medical event deemed such by medical or scientific judgement.

    Time frame: Up to approximately 10 weeks

  4. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 8 weeks

Secondary outcomes

  1. Change from Baseline in Wakefulness after Persistent Sleep Onset at Week 8

    Wakefulness after persistent sleep onset will be measured in a sleep laboratory by polysomnography at the participant's habitual bedtime. Change from baseline in wakefulness after persistent sleep onset at Week 8 will be reported.

    Time frame: Baseline and Week 8

  2. Number of Participants Who are Positive for Substance Abuse at Day 1

    A positive assessment for substance abuse at Day 1 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.

    Time frame: Day 1

  3. Number of Participants Who are Positive for Substance Abuse at Day 4

    A positive assessment for substance abuse at Day 4 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.

    Time frame: Day 4

  4. Number of Participants Who are Positive for Substance Abuse at Week 2

    A positive assessment for substance abuse at Week 2 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.

    Time frame: Week 2

  5. Number of Participants Who are Positive for Substance Abuse at Week 4

    A positive assessment for substance abuse at Week 4 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.

    Time frame: Week 4

  6. Number of Participants Who are Positive for Substance Abuse at Week 8

    A positive assessment for substance abuse at Week 8 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.

    Time frame: Week 8

  7. Number of Participants with Positive Urine Drug Screen

    A positive urine drug screen is defined as urine drug test positive for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis

    Time frame: Day 1, Day 4, Week 2, Week 4, Week 8

07

Study locations

13 of 13 sites recruiting
  • Cenexel CNS ( Site 2012)
    Garden Grove, California 92845, United States
    Recruiting
    • Study Coordinator · Contact866-787-4257
  • Yale University School of Medicine ( Site 1003)
    New Haven, Connecticut 06520, United States
    Recruiting
    • Study Coordinator · Contact203-785-3627
  • Bradenton Research Center ( Site 2021)
    Bradenton, Florida 34205, United States
    Recruiting
    • Study Coordinator · Contact941-708-0005
  • CenExel iResearch, LLC ( Site 2010)
    Savannah, Georgia 31405, United States
    Recruiting
    • Study Coordinator · Contact912-744-0800
  • Johns Hopkins University ( Site 1001)
    Baltimore, Maryland 21224, United States
    Recruiting
    • Study Coordinator · Contact443-216-9237
  • Hassman Research Institute Marlton Site ( Site 2005)
    Marlton, New Jersey 08053, United States
    Recruiting
    • Study Coordinator · Contact856-261-6420
  • The Rivus Wellness & Research Institute ( Site 2014)
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
    • Study Coordinator · Contact405-607-2233
  • Penn Medicine University of Pennsylvania Health System- Center for Studies of Addiction ( Site 1006)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact215-222-3200
  • Butler Hospital ( Site 1002)
    Providence, Rhode Island 02906, United States
    Recruiting
    • Study Coordinator · Contact401-455-6440
  • Medical University of South Carolina ( Site 1005)
    Charleston, South Carolina 29403, United States
    Recruiting
    • Study Coordinator · Contact843-792-4636
  • Adams Clinical Dallas ( Site 2007)
    DeSoto, Texas 75115, United States
    Recruiting
    • Study Coordinator · Contact972-283-6286
  • Memorial Hermann Village ( Site 2001)
    Houston, Texas 77043, United States
    Recruiting
    • Study Coordinator · Contact281-369-5765
  • VCU Institute for Drug and Alcohol Studies ( Site 1004)
    Richmond, Virginia 23219, United States
    Recruiting
    • Study Coordinator · Contact804-827-3784
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 20 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 24, 2024
StartActual
Oct 9, 2025
Primary completionEst.
Jun 24, 2027
CompletionEst.
Jun 24, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655883
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Oct 9, 2025
Primary completion
Jun 24, 2027 (estimated)
Completion
Jun 24, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvorexant

Start the discussion